{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:53:39Z","timestamp":1781895219629,"version":"3.54.5"},"reference-count":55,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Gonadotropin-releasing hormone (GnRH) analogs are widely used in the treatment of hormone-dependent conditions such as prostate cancer, breast cancer, and central precocious puberty. These agents suppress sex hormone secretion by persistently downregulating the hypothalamic-pituitary-gonadal axis. To improve convenience and adherence, various long-acting injectable formulations, administered monthly, quarterly, or every 6 months, have been developed. However, there is ongoing debate regarding the relative advantages and optimal choice among these formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Evidence from clinical trials and real-world studies suggests that the efficacy and safety of multimonthly formulations are equivalent to or noninferior to those of monthly variants and produce similar clinical outcomes in hormone suppression and disease control. In addition, multimonthly injections are associated with fewer hospital visits, improved adherence to treatment, lower indirect costs, and improved quality of life for patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although differences in pharmacokinetics and initial hormonal responses have been observed, they do not translate into meaningful differences in clinical outcomes. Long-acting GnRH analogs are equally effective and offer a more efficient, patient-centered approach to managing hormone-dependent diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag172","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:44:32Z","timestamp":1780746272000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-acting vs monthly GnRH agonists: A comprehensive review of efficacy, safety, and health-system implications"],"prefix":"10.1093","author":[{"given":"Hamed","family":"Ghiami","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Damghan Branch, Islamic Azad University , Damghan ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Arasteh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences , Mashhad ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Omidkhoda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences , Mashhad ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"22","key":"2026061914154509900_zxag172-B1","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","article-title":"Clinical practice. Precocious puberty","volume":"358","author":"Carel","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"2026061914154509900_zxag172-B2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.6065\/apem.2013.18.4.173","article-title":"Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75\u2005mg) for efficacy and safety in girls with central precocious puberty","volume":"18","author":"Kim","year":"2013","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"suppl 1","key":"2026061914154509900_zxag172-B3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1515\/jpem.2000.13.s1.739","article-title":"Hormonal changes during GnRH analogue therapy in children with central precocious puberty","volume":"13","author":"M\u00fcller","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"2026061914154509900_zxag172-B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.6065\/apem.2014.19.1.27","article-title":"Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty","volume":"19","author":"Baek","year":"2014","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"4","key":"2026061914154509900_zxag172-B5","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","author":"Carel","year":"2009","journal-title":"Pediatrics"},{"issue":"24","key":"2026061914154509900_zxag172-B6","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1200\/jco.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026061914154509900_zxag172-B7","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/jco.2002.09.112","article-title":"Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer\u2014Austrian Breast and Colorectal Cancer Study Group Trial 5","volume":"20","author":"Jakesz","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026061914154509900_zxag172-B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jnci\/djn498","article-title":"Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer","volume":"101","author":"Hackshaw","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1 suppl 4","key":"2026061914154509900_zxag172-B9","doi-asserted-by":"publisher","first-page":"101335","DOI":"10.1016\/j.esmoop.2023.101335","article-title":"111P Goserelin 3 monthly depot is noninferior to goserelin monthly depot in the treatment of breast cancer: a real-world evidence study","volume":"8","author":"Wu","year":"2023","journal-title":"ESMO Open"},{"key":"2026061914154509900_zxag172-B10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/cmr.S12700","article-title":"Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort","volume":"3","author":"Crawford","year":"2011","journal-title":"Cancer Manag Res"},{"issue":"3","key":"2026061914154509900_zxag172-B11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2165\/11202230-000000000-00000","article-title":"Triptorelin embonate (6-month formulation)","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"issue":"12","key":"2026061914154509900_zxag172-B12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2165\/11319690-000000000-00000","article-title":"Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study","volume":"29","author":"Lundstr\u00f6m","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"12","key":"2026061914154509900_zxag172-B13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1517\/14656566.2013.806489","article-title":"Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties","volume":"14","author":"Bertelloni","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2026061914154509900_zxag172-B14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/beem.2002.0188","article-title":"Treatment of central precocious puberty","volume":"16","author":"Partsch","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2026061914154509900_zxag172-B15","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1210\/jc.2013-1024","article-title":"Treatment and outcomes of precocious puberty: an update","volume":"98","author":"Fuqua","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061914154509900_zxag172-B16","doi-asserted-by":"publisher","first-page":"1390674","DOI":"10.3389\/fendo.2024.1390674","article-title":"Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment","volume":"15","author":"Thaneetrakool","year":"2024","journal-title":"Front Endocrinol"},{"issue":"3","key":"2026061914154509900_zxag172-B17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.5114\/aoms.2014.43743","article-title":"Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard\/Depo-Eligard) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study","volume":"10","author":"Braeckman","year":"2014","journal-title":"Arch Med Sci"},{"issue":"2","key":"2026061914154509900_zxag172-B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40487-018-0087-1","article-title":"Effects of initiating or switching to a six-monthly triptorelin formulation on prostate cancer patient\u2014healthcare interactions and hospital resource use: a real-world, retrospective, non-interventional study","volume":"6","author":"Cornford","year":"2018","journal-title":"Oncol Ther"},{"issue":"suppl 1","key":"2026061914154509900_zxag172-B19","first-page":"1","article-title":"A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer","volume":"26","author":"Dijkman","year":"1994","journal-title":"Eur Oncol"},{"issue":"1","key":"2026061914154509900_zxag172-B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000475122","article-title":"A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. the Dutch South East Cooperative Urological Group","volume":"27","author":"Dijkman","year":"1995","journal-title":"Eur Urol"},{"issue":"5","key":"2026061914154509900_zxag172-B21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000081629","article-title":"Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer","volume":"62","author":"Teillac","year":"2004","journal-title":"Hormone Res"},{"issue":"3","key":"2026061914154509900_zxag172-B22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0022-5347(05)64560-0","article-title":"Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer","volume":"168","author":"Sharifi","year":"2002","journal-title":"J Urol"},{"issue":"suppl 1","key":"2026061914154509900_zxag172-B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000056540","article-title":"Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer","volume":"60","author":"Tunn","year":"1998","journal-title":"Urol Int"},{"issue":"2","key":"2026061914154509900_zxag172-B24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0090-4295(03)00330-3","article-title":"An eight-month clinical study of LA-2575 30.0\u2005mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer","volume":"62","author":"Sartor","year":"2003","journal-title":"Urology"},{"issue":"2","key":"2026061914154509900_zxag172-B25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bju.13482","article-title":"Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer","volume":"119","author":"Shore","year":"2017","journal-title":"BJU Int"},{"issue":"4","key":"2026061914154509900_zxag172-B26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000100579","article-title":"Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty","volume":"68","author":"Isaac","year":"2007","journal-title":"Hormone Res"},{"key":"2026061914154509900_zxag172-B27","doi-asserted-by":"publisher","first-page":"1043293","DOI":"10.1155\/2022\/1043293","article-title":"Efficacy of leuprorelin 3-month depot (11.25\u2005mg) compared to 1-month depot (3.75\u2005mg) for central precocious puberty in Chinese girls: a prospective cohort study","volume":"2022","author":"Yang","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"34","key":"2026061914154509900_zxag172-B28","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.3346\/jkms.2021.36.e219","article-title":"Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of Korean girls with central precocious puberty in single tertiary center","volume":"36","author":"Chung","year":"2021","journal-title":"J Korean Med Sci"},{"issue":"6","key":"2026061914154509900_zxag172-B29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1159\/000441497","article-title":"Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin","volume":"84","author":"Bertelloni","year":"2015","journal-title":"Hormone Rese Paediatr"},{"issue":"6","key":"2026061914154509900_zxag172-B30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jpeds.2011.05.036","article-title":"A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty","volume":"159","author":"Fuld","year":"2011","journal-title":"J Pediatrics"},{"issue":"2","key":"2026061914154509900_zxag172-B31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-010-1332-y","article-title":"Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer","volume":"126","author":"Masuda","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2026061914154509900_zxag172-B32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-025-07656-z","article-title":"Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study","volume":"211","author":"McCann","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2026061914154509900_zxag172-B33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12282-015-0637-4","article-title":"Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer","volume":"23","author":"Noguchi","year":"2016","journal-title":"Breast Cancer"},{"issue":"10","key":"2026061914154509900_zxag172-B34","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/jnci\/djae115","article-title":"Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor-positive breast cancer","volume":"116","author":"Lin","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2026061914154509900_zxag172-B35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12032-012-0354-1","article-title":"Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients","volume":"30","author":"Aydiner","year":"2013","journal-title":"Med Oncol"},{"issue":"2","key":"2026061914154509900_zxag172-B36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.fertnstert.2003.07.013","article-title":"Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis","volume":"81","author":"Donnez","year":"2004","journal-title":"Fertil Steril"},{"issue":"12","key":"2026061914154509900_zxag172-B37","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/oxfordjournals.humrep.a019199","article-title":"Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study","volume":"11","author":"Crosignani","year":"1996","journal-title":"Hum Reprod"},{"issue":"4","key":"2026061914154509900_zxag172-B38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/eje.0.1500533","article-title":"Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty","volume":"150","author":"Arrigo","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026061914154509900_zxag172-B39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jcem.84.1.5409","article-title":"Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty","volume":"84","author":"Feuillan","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026061914154509900_zxag172-B40","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1210\/jcem.84.12.6203","article-title":"Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function","volume":"84","author":"Heger","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026061914154509900_zxag172-B41","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1210\/jcem.84.12.6204","article-title":"Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty","volume":"84","author":"Palmert","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026061914154509900_zxag172-B42","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1210\/jcem.87.5.8481","article-title":"Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height","volume":"87","author":"Lazar","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061914154509900_zxag172-B43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/adc.75.4.292","article-title":"Final height in central precocious puberty after long term treatment with a slow release GnRH agonist","volume":"75","author":"Oostdijk","year":"1996","journal-title":"Arch Dis Child"},{"issue":"5","key":"2026061914154509900_zxag172-B44","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2265.2004.02146.x","article-title":"Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty","volume":"61","author":"Paterson","year":"2004","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2026061914154509900_zxag172-B45","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/jcem.87.2.8202","article-title":"Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy","volume":"87","author":"van der Sluis","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"51","key":"2026061914154509900_zxag172-B46","doi-asserted-by":"publisher","first-page":"35746","DOI":"10.1074\/jbc.M109.063917","article-title":"Pulsatile and sustained gonadotropin-releasing hormone (GnRH) receptor signaling: does the Ca2+\/NFAT signaling pathway decode GnRH pulse frequency?","volume":"284","author":"Armstrong","year":"2009","journal-title":"J Biol Chem"},{"issue":"9","key":"2026061914154509900_zxag172-B47","doi-asserted-by":"publisher","first-page":"e4727","DOI":"10.1002\/pro.4727","article-title":"Growth hormone receptor agonists and antagonists: from protein expression and purification to long-acting formulations","volume":"32","author":"Wang","year":"2023","journal-title":"Protein Sci"},{"key":"2026061914154509900_zxag172-B48","doi-asserted-by":"publisher","first-page":"968485","DOI":"10.3389\/fped.2022.968485","article-title":"Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States","volume":"10","author":"Popovic","year":"2022","journal-title":"Front Pediatr"},{"issue":"5","key":"2026061914154509900_zxag172-B49","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1210\/jc.2005-1500","article-title":"Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty","volume":"91","author":"Badaru","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"2026061914154509900_zxag172-B50","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1515\/jpem.2000.13.s1.723","article-title":"Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics","volume":"13","author":"Lahlou","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"2026061914154509900_zxag172-B51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00228-014-1682-1","article-title":"Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer","volume":"70","author":"Eckstein","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2026061914154509900_zxag172-B52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/CEOR.S44855","article-title":"Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation","volume":"5","author":"Wex","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"issue":"11","key":"2026061914154509900_zxag172-B53","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/13696998.2017.1362410","article-title":"Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations","volume":"20","author":"Goto","year":"2017","journal-title":"J Med Econ"},{"issue":"11","key":"2026061914154509900_zxag172-B54","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13696998.2017.1364647","article-title":"Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations","volume":"20","author":"Goto","year":"2017","journal-title":"J Med Econ"},{"key":"2026061914154509900_zxag172-B55","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/ceor.S485856","article-title":"Resources utilization assessment and cost-minimization analysis of the 6-monthly formulation of triptorelin in the treatment of prostate cancer in China","volume":"16","author":"Chen","year":"2024","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag172\/68486850\/zxag172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag172\/68486850\/zxag172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:15:53Z","timestamp":1781892953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag172\/8703615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag172","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"zxag172"}}